Context Therapeutics Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
CNTX Nasdaq 2830 www.contexttherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Context Therapeutics Inc.

Context doses first subject in Phase I cancer trial of CTIM-76 - Jan 15th, 2025 4:29 pm
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76 - Jan 14th, 2025 9:58 pm
Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors - Jan 13th, 2025 12:30 pm
Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results - Nov 6th, 2024 9:06 pm
Context Therapeutics to Participate in Upcoming Investor Conferences in November - Oct 23rd, 2024 11:30 am
Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting - Oct 16th, 2024 11:30 am
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody - Sep 23rd, 2024 11:30 am
We Think Context Therapeutics (NASDAQ:CNTX) Can Afford To Drive Business Growth - Sep 16th, 2024 12:42 pm
Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year? - Sep 12th, 2024 1:40 pm
Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors - Sep 4th, 2024 11:30 am
Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results - Aug 7th, 2024 8:17 pm
Context Therapeutics Inc.'s (NASDAQ:CNTX) top owners are individual investors with 52% stake, while 30% is held by private equity firms - Aug 6th, 2024 10:13 am
Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations - Aug 1st, 2024 11:30 am
Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95 - Jul 10th, 2024 11:30 am
Is CareCloud (CCLD) Stock Outpacing Its Medical Peers This Year? - Jun 12th, 2024 1:40 pm
Hypergrowth Hits: 3 Stocks Clocking Triple-Digit Gains with No End in Sight - May 30th, 2024 10:11 am
The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains - May 23rd, 2024 12:50 am
Are You Looking for a Top Momentum Pick? Why Context Therapeutics Inc. (CNTX) is a Great Choice - May 20th, 2024 4:00 pm
Context Therapeutics Inc. (CNTX) Upgraded to Buy: Here's Why - May 14th, 2024 4:00 pm
Context Therapeutics Reports First Quarter 2024 Operating and Financial Results - May 8th, 2024 8:06 pm